Form 4: 4D Molecular Therapeutics Chief Legal Officer Exercises Options and Sells Shares

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On February 27, 2024, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options to acquire 1,909 shares of common stock at a price of $20.24 per share.
• Simultaneously, Bizily sold 1,909 shares of common stock at $30 per share.
• Following these transactions, Bizily directly owns 1,737 shares of 4D Molecular Therapeutics.
• The transactions were executed under a pre-arranged 10b5-1 trading plan adopted on October 10, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine insider trading activity under a pre-arranged plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to trade company stock.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Comparison to Industry Standards

• Insider transactions are common in publicly traded companies, and the use of 10b5-1 trading plans is a standard practice to avoid accusations of illegal insider trading.
• The details of the vesting schedule are typical for stock option grants.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they provide insight into insider sentiment, but the pre-arranged nature of the trading plan mitigates concerns about opportunistic trading.

Key Dates